目的 觀察乙酰吉他霉素干混懸劑治療兒童肺炎支原體肺炎的臨床療效及安全性。方法 選擇2022年4月-2023年5月肇慶市婦幼保健院收治的肺炎支原體肺炎患兒為研究對象，隨機分為試驗組（乙酰吉他霉素干混懸劑組）及對照組（阿奇霉素干混懸劑組）。兩組同時給予常規(guī)治療，包括給予退熱、止咳、平喘等基礎對癥治療，療程1~2周。比較兩組患兒治療后的臨床療效，觀察癥狀消退情況及治療期間藥物不良反應發(fā)生情況。結果 試驗組60例和對照組60例納入分析，試驗期間有6例患兒脫落或失訪。治療后，兩組的總有效率均為100%，無統(tǒng)計學差異。兩組藥物均可有效改善患者發(fā)熱、濕啰音、咳嗽、咳痰等癥狀。訪視1[首次用藥后（5±2） d]時，乙酰吉他霉素干混懸劑在濕啰音較基線改善率、顯效率方面優(yōu)于阿奇霉素，可能乙酰吉他霉素治療肺炎支原體肺炎起效更快。訪視2[首次用藥后（10±2） d]時，乙酰吉他霉素干混懸劑在咳嗽癥狀緩解率方面優(yōu)于阿奇霉素，但未能排除年齡因素對結論的影響。治療期間，試驗組和對照組的藥物不良反應發(fā)生率差異無統(tǒng)計學意義（P>0.05）。依從性調研發(fā)現(xiàn)，兩組患者依從性評價良好，差異無統(tǒng)計學意義（P>0.05）。結論 乙酰吉他霉素干混懸劑可有效治療兒童肺炎支原體肺炎，患兒依從性好，耐受性好。乙酰吉他霉素干混懸劑治療可快速有效緩解咳嗽、濕啰音等臨床癥狀癥狀，具有一定優(yōu)勢。

Objective To observe the clinical efficacy and safety of Acetylkitasamycin Dry Suspension on Mycoplasma pneumoniae pneumonia (MPP) in children. Methods From April 2022 to May 2023, the children with MPP diagnosed in Zhaoqing Maternal and Child Health Hospital were collected as the research objects. The subjects were randomly divided into a treatment group (oral administrate Acetylkitasamycin Dry Suspension) and a control group (oral administrate Azithromycin Dry Suspension). The two groups were given routine treatment,including basic symptomatic treatment such as antipyretic,relieving cough, resolving phlegm and relieving asthma, The treatment last for 1-2 weeks. Compare with the clinical efficacy of the two groups after treatment, disappearance and adverse drug reactions during treatment were compared before and after treatment. Results There were 60 cases in treatment group and 60 cases in control group. During the treatment period,six children were dropped out or lost to follow-up. Two group drugs can effectively improve the symptoms of fever, cough,sputum and pans. At interview 1 [(5±2) days after the first dose], the improvement rate of crackles baseline and efficiency in the Acetylkitasamycin Dry Suspension group were better than that in Azithromycin group, which may indicate that acetylkitasamycin has a faster effect on MPP. At the interview 2 [(10±2) days after the first administration], Acetylkitasamycin Dry Suspension had a better remission rate of cough symptoms than azithromycin, but could not be ruled out the influence of ages. During the treatment period, the incidences of adverse drug reactions in treatment group and control group during treatment were no significant difference (P > 0.05).Through the survey of compliance, two groups have good medical compliance. Conclusion Acetylguitamycin Dry Suspension can effectively treat MPP Children with good compliance and tolerance. Acetylkitasamycin Dry Suspension has good clinical efficacy in treatment of children with MPP advantages in onset time and remission rate of cough symptoms.

R974

廣東省肇慶市科技創(chuàng)新指導類立項項目（2022040310001）